Cargando…
Tafolecimab in Chinese patients with non-familial hypercholesterolemia (CREDIT-1): a 48-week randomized, double-blind, placebo-controlled phase 3 trial
BACKGROUND: Tafolecimab, a fully human proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody developed for the treatment of hypercholesterolemia, demonstrated robust lipid-lowering efficacy and favorable safety in previous short-term studies. We aimed to assess the long-term effi...
Autores principales: | Huo, Yong, Chen, Beijian, Lian, Qiufang, Wang, Shuqing, Liu, Lu, Lu, Di, Qu, Yanling, Zheng, Guanzhong, Li, Lipeng, Ji, Yuan, Yin, Guotian, Huang, Wenjun, Xie, Ying, Yang, Xinchun, Gao, Xiufang, An, Pei, Xue, Fengtai, Li, Haoyu, Deng, Huan, Li, Li, Pei, Lijuan, Qian, Lei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558773/ https://www.ncbi.nlm.nih.gov/pubmed/37808342 http://dx.doi.org/10.1016/j.lanwpc.2023.100907 |
Ejemplares similares
-
Tafolecimab in Chinese Patients With Hypercholesterolemia (CREDIT-4): A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
por: Qi, Litong, et al.
Publicado: (2023) -
Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)
por: Chai, Meng, et al.
Publicado: (2023) -
Tafolecimab, A Novel Member of PCSK9 Monoclonal Antibodies, Is Worth Expecting in a Chinese Population
por: Li, Jian-Jun
Publicado: (2023) -
A Component Formula of Chinese Medicine for Hypercholesterolemia Based on Virtual Screening and Biology Network
por: Huo, Xiaoqian, et al.
Publicado: (2018) -
Credit Where Credit is Due
Publicado: (2009)